REPLACED BY ART 34 AMDT

We claim:

1. A compound of the formula:

$$R1$$
 $R2$
 $R4$
 $R3$
 $R3$

wherein:

R1 can be an acidic group selected from the group consisting of carboxyl, phosphono, phosphino, sulfono, sulfono, borono, tetrazol, isoxazol, -CH₂-carboxyl, -CH₂-phosphono, -CH₂-phosphino, -CH₂-sulfono, -CH₂-sulfono, -CH₂-borono, -CH₂-tetrazol, and -CH₂-isoxazol;

R2 can be a basic group selected from the group consisting of 1° amino, 2° amino, 3° amino, quaternary ammonium salts, aliphatic 1° amino, aliphatic 2° amino, aliphatic 3° amino, aliphatic quaternary ammonium salts, aromatic 1° amino, aromatic 2° amino, aromatic 3° amino, aromatic quaternary ammonium salts, imidazol, guanidino, boronoamino, allyl, urea, thiourea,

R3 can be H, aliphatic, aromatic or heterocyclic;

R4 can be an acidic group selected from the group consisting of carboxyl, phosphono, phosphino, sulfono, sulfono, borono, tetrazol, isoxazol; and pharmaceutically acceptable salts thereof.

2. A compound as claimed in claim 1, wherein R1 is COOH

- 3. A compound as claimed in claim 1, wherein R2 is COOH
- 4. A compound as claimed in claim 1, wherein R3 can be -H, or -Me; or xanthyl or thioxanthyl and R4 is NH₂
- 5. A process for the preparation of a compound of Formula I, or a pharmaceutically acceptable metabolically-labile ester or amide thereof, or a pharmaceutically acceptable salt thereof, which comprises:
 - (a) hydrolyzing a compound of formula:

in which **R1** is defined as above, **R5** represents a hydrogen atom or an acyl group and **R4** has the meaning defined above. Preferred values for **R5** are hydrogen and (2-6C) alkanoyl groups, such as acetyl;

(b) hydrolyzing a compound of formula:


$$\begin{array}{c}
R \\
R \\
4 \\
N \\
R \\
7
\end{array}$$

$$\begin{array}{c}
O \\
N \\
R \\
6 \\
O
\end{array}$$
(111)

wherein R6 and R7 each independently represent a hydrogen atom, a (2-6C) alkanoyl

group, a (1-4C) alkyl group, a (3-4C) alkenyl group or a phenyl (1-4C) alkyl group in which the phenyl is unsubstituted or substituted by halogen, (1-4C) alkyl or (1-4C) alkoxy, or a salt thereof; or

(c) deprotecting a compound of formula:




in which R8 represents a hydrogen atom or a carboxyl protecting group, or a salt thereof, and R9 represents a hydrogen atom or a nitrogen protecting group;

whereafter, if necessary and/or desired:


- (i) resolving the compound of Formula I;
- (ii) converting the compound of Formula I into a non-toxic metabolically-labile ester or amide thereof; and/or;
- (iii) converting the compound of Formula I or a non-toxic metabolically-labile ester or amide thereof into a pharmaceutically acceptable salt thereof.
- 6. A pharmaceutical formulation, which comprises a compound as claimed in claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.
- 7. A method of modulating one or more metabotropic glutamate receptor functions in a warm blooded mammal requiring such treatment, which comprises administering an effective amount of a compound as claimed in claim 1.

8. A compound of formula:




in which R1, R4 and R5 have the meanings as defined above. in claim 1.

9. A compound of formula:



wherein R6 and R7 have meanings as defined above.

10. A compound of formula:



in which R8 and R9 have meanings as defined above.